Correction to“Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer”

Guan X,Ma F,Xu B.Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer.Cancer Innovation.2022;1-5.In the funding information,the Grant/Award Number of National Nature Science Foundation of China was incorrect.The Grant/Award Number should be“82103634”.We apologize for this error.